Bayesian analysis from phase III trials were underused and poorly reported: a systematic review.

Date publication

avril 2020

Journal

Journal of clinical epidemiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas

Tous les auteurs :
Ferreira D, Vivot A, Diemunsch P, Meyer N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32259583

Résumé

We assessed the reporting of replicability items with the BayesWatch guidelines and crucial items of Bayesian analyses with the ROBUST guidelines in reports of phase III trials.

Mots clés

Bayes, RCT, phase III, replicability

Référence

J Clin Epidemiol. 2020 Apr 4;: